Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. more
Time Frame | OCGN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -13.33% | -2.06% | -0.55% |
1-Month Return | -17.25% | -1.92% | 2.72% |
3-Month Return | -32.68% | -10.4% | 7.66% |
6-Month Return | -45.36% | -4.6% | 10.15% |
1-Year Return | 102.69% | 4.06% | 27.53% |
3-Year Return | -85.42% | 1.94% | 32.31% |
5-Year Return | 96.35% | 36.48% | 89.2% |
10-Year Return | -99.89% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 42.62K | 42.62K | 22.92K | 2.49M | 6.04M | [{"date":"2019-12-31","value":0.71,"profit":true},{"date":"2020-12-31","value":0.71,"profit":true},{"date":"2021-12-31","value":0.38,"profit":true},{"date":"2022-12-31","value":41.22,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 60.61K | 6.35K | 589.00K | 1.07M | 704.00K | [{"date":"2019-12-31","value":5.65,"profit":true},{"date":"2020-12-31","value":0.59,"profit":true},{"date":"2021-12-31","value":54.89,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":65.61,"profit":true}] |
Gross Profit | (60.61K) | 36.27K | (589.00K) | (1.07M) | 5.33M | [{"date":"2019-12-31","value":-1.14,"profit":false},{"date":"2020-12-31","value":0.68,"profit":true},{"date":"2021-12-31","value":-11.05,"profit":false},{"date":"2022-12-31","value":-20.12,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (142.21%) | 85.09% | (2569.81%) | (43.13%) | 88.34% | [{"date":"2019-12-31","value":-160.98,"profit":false},{"date":"2020-12-31","value":96.33,"profit":true},{"date":"2021-12-31","value":-2909.11,"profit":false},{"date":"2022-12-31","value":-48.82,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 14.16M | 14.33M | 58.03M | 84.87M | 71.57M | [{"date":"2019-12-31","value":16.69,"profit":true},{"date":"2020-12-31","value":16.88,"profit":true},{"date":"2021-12-31","value":68.37,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":84.33,"profit":true}] |
Operating Income | (14.16M) | (21.28M) | (58.03M) | (84.87M) | (65.53M) | [{"date":"2019-12-31","value":-1416261900,"profit":false},{"date":"2020-12-31","value":-2128471700,"profit":false},{"date":"2021-12-31","value":-5802800000,"profit":false},{"date":"2022-12-31","value":-8486800000,"profit":false},{"date":"2023-12-31","value":-6553100000,"profit":false}] |
Total Non-Operating Income/Expense | (7.85M) | (1.26M) | (468.00K) | - | - | [{"date":"2019-12-31","value":-784663300,"profit":false},{"date":"2020-12-31","value":-125685100,"profit":false},{"date":"2021-12-31","value":-46800000,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (20.24M) | (21.82M) | (58.42M) | (81.35M) | (63.08M) | [{"date":"2019-12-31","value":-2024263000,"profit":false},{"date":"2020-12-31","value":-2182195300,"profit":false},{"date":"2021-12-31","value":-5841700000,"profit":false},{"date":"2022-12-31","value":-8135100000,"profit":false},{"date":"2023-12-31","value":-6307800000,"profit":false}] |
Income Taxes | 982.96K | 801.51K | (52.00K) | (4.00M) | 536.11K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":81.54,"profit":true},{"date":"2021-12-31","value":-5.29,"profit":false},{"date":"2022-12-31","value":-406.63,"profit":false},{"date":"2023-12-31","value":54.54,"profit":true}] |
Income After Taxes | (21.23M) | (22.62M) | (58.37M) | - | - | [{"date":"2019-12-31","value":-2122559300,"profit":false},{"date":"2020-12-31","value":-2262346800,"profit":false},{"date":"2021-12-31","value":-5836500000,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (20.24M) | (21.82M) | (58.37M) | (81.35M) | (63.08M) | [{"date":"2019-12-31","value":-2024263000,"profit":false},{"date":"2020-12-31","value":-2182195300,"profit":false},{"date":"2021-12-31","value":-5836500000,"profit":false},{"date":"2022-12-31","value":-8135100000,"profit":false},{"date":"2023-12-31","value":-6307800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (21.23M) | (22.62M) | (58.37M) | (77.83M) | (63.08M) | [{"date":"2019-12-31","value":-2122559300,"profit":false},{"date":"2020-12-31","value":-2262346800,"profit":false},{"date":"2021-12-31","value":-5836500000,"profit":false},{"date":"2022-12-31","value":-7783400000,"profit":false},{"date":"2023-12-31","value":-6307800000,"profit":false}] |
EPS (Diluted) | (4.34) | (0.31) | (0.29) | (0.38) | (0.24) | [{"date":"2019-12-31","value":-434,"profit":false},{"date":"2020-12-31","value":-31,"profit":false},{"date":"2021-12-31","value":-29,"profit":false},{"date":"2022-12-31","value":-38,"profit":false},{"date":"2023-12-31","value":-24,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
OCGN | |
---|---|
Cash Ratio | 2.46 |
Current Ratio | 2.58 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
OCGN | |
---|---|
ROA (LTM) | -47.98% |
ROE (LTM) | -103.29% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
OCGN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.34 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.66 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
OCGN | |
---|---|
Trailing PE | NM |
Forward PE | 15.22 |
P/S (TTM) | 52.51 |
P/B | 6.07 |
Price/FCF | NM |
EV/R | 45.72 |
EV/Ebitda | NM |
Ocugen Inc (OCGN) share price today is $0.7545
Yes, Indians can buy shares of Ocugen Inc (OCGN) on Vested. To buy Ocugen Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in OCGN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Ocugen Inc (OCGN) via the Vested app. You can start investing in Ocugen Inc (OCGN) with a minimum investment of $1.
You can invest in shares of Ocugen Inc (OCGN) via Vested in three simple steps:
The 52-week high price of Ocugen Inc (OCGN) is $2.1. The 52-week low price of Ocugen Inc (OCGN) is $0.37.
The price-to-earnings (P/E) ratio of Ocugen Inc (OCGN) is
The price-to-book (P/B) ratio of Ocugen Inc (OCGN) is 6.07
The dividend yield of Ocugen Inc (OCGN) is 0.00%
The market capitalization of Ocugen Inc (OCGN) is $246.78M
The stock symbol (or ticker) of Ocugen Inc is OCGN